See all PSTI articles @ Daily Dose
Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration.
Data from two Phase I safety and dose determining clinical trials indicate that Pluristem's first PLX product candidate, PLX-PAD, is safe and potentially effective for the treatment of end stage peripheral artery disease. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in treating nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically.
Pluristem has a strong patent portfolio, GMP certified manufacturing, research and development facilities, strategic relationships with major research institutions and a seasoned management team.
For more information visit www.pluristem.com and follow Pluristem on Twitter @Pluristem, the contents of which are not part of this press release.
CLICK HERE to watch a video where CLI patients and doctors involved in the clinical trials share their stories.
